Research - Bellicum is a cell therapy developer with a pipeline of early therapeutics, including the now-ubiquitous chimeric antigen receptor T cell candidates (a la Juno Therapeutics (JUNO) and Kite (KITE)) and T cell receptor (TCR) candidates, neither of which will enter the clinic until next year.
PremiumInsights - Monday morning was jam-packed with deal flow in biotech. Here's a 60-second primer.
Read nowInsights - Threshold Pharmaceuticals (THLD) announced that the target enrollment of 620 patients with advanced soft tissue sarcoma has been achieved in the company’s pivotal phase 3 … Continue Reading
Read nowLong Ideas - Update: On the morning of July 15th, Curis announced that the European Commission granted the conditional approval of Erivedge (vismodegib) for the treatment of adult patients with … Continue Reading
Read nowLong Ideas - Cadence (CADX) was a compelling buy last year as the sales ramp for its IV acetaminophen formulation began to improve. A position since Mr. King … Continue Reading
Read nowLong Ideas - The EMA’s advisory body took investors by surprise on Friday and announced that they would be recommending Halozyme (HALO) and Baxter’s (BAX) HyQvia for approval … Continue Reading
Read now
